Previous Article | Next Article ![]()
Journal of Bacteriology, October 2004, p. 6457-6464, Vol. 186, No. 19
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.19.6457-6464.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Sung Gu Lee, Weon Sup Lee, and Si Myung Byun*
Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Korea
Received 23 March 2004/ Accepted 28 May 2004
|
|
|---|
|
|
|---|
Many bacterial proteolytic enzymes are synthesized as inactive precursors, or zymogens, to prevent unwanted protein degradation and to enable spatial and temporal regulation of proteolytic activity (12). Biochemical studies of the activation mechanism of individual proteases have provided insights into their physiological functions. Every extracellular protease in B. subtilis is synthesized as a preproenzyme in the cytoplasm and is processed to a mature enzyme in the extracellular milieu. The activation mechanism of B. subtilis subtilisin has been well studied. The zymogen form of subtilisin is converted to an active form via intramolecular autoprocessing (19) in the extracellular space (9). The propeptide has been shown to guide the proper folding of subtilisin in vivo and in vitro (34). Most extracellular proteases in B. subtilis seem to be activated by autoprocessing. However, the Mpr protease might be an exception in that it is not able to activate itself. Reportedly, Mpr has a high substrate specificity, recognizing a glutamic acid residue as a P1 cleavage site (20). However, a glutamic acid residue is not present in the Mpr propeptide cleavage site, suggesting that it is not autoprocessed. Many glutamic-acid-specific proteases such as V8 protease (5) and SPase (43) have been found in Staphylococcus aureus and some nonpathogenic bacteria (10, 13, 42); however, the processing mechanisms of glutamyl endopeptidases have not been clearly defined.
Here, we report that Mpr can be specifically activated by other extracellular proteases and that Mpr can be converted to an autoproteolytic protease by placing a glutamic acid residue in the propeptide cleavage site. The molecular evolution of protease activation mechanisms in B. subtilis is also discussed.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Strains and plasmids used in this study
|
Construction of mpr and bpr expression vectors. The subtilisin promoter from pSM704 (15) was PCR amplified with two primers, SP-F (5'-GCCGTCTGTACGTTCCTTAAG) and SP-R (5'-TCTGAGCTCTCTCCTTTTAAAAAA). The EcoRI- and SacI-digested PCR product was subcloned into EcoRI-SacI-digested pSM704 for the removal of the signal sequences. The resulting plasmid was termed pSP704. The mpr gene was amplified from genomic DNA of B. subtilis 168 with primers Mpr-F (5'-AGGGAGCTCACAAAATGAAAT) and Mpr-R (5'-ATGGATCCTTATTGCCCAATATTGAATAT). The mpr PCR product (1.0 kb) and pSP704, both digested with SacI and BamHI, were ligated to create pMpr, where expression of the mpr gene is controlled by the subtilisin promoter. To facilitate detection of the Mpr protein, we introduced a C-terminal His tag in the mpr gene product as follows: the mpr gene was amplified with Mpr-F and MprH6-R (5'-ATGGATCCTTAATGATGATGATGATGATGACTACTTCCTTGATTTGCCCAATATTGAAT), and the SacI- and BamHI-digested PCR product was inserted into SacI- and BamHI-digested pSP704 to make pMprH6.
The bpr gene was amplified from genomic DNA of B. subtilis 168 with primers Bpr-F (5'-GGGGAGCTCAATGAGGAAAAAAACGAA AAACAGACTCAT)and Bpr-R (5'-TTGGATCCACTTAATTTTCTGTGTTCATATTAAGTTTT). The bpr PCR product (1.0 kb) and pSP704, both digested with SacI and BamHI, were ligated to make pBpr.
Construction of gene disruption vectors. bpr (4.5 kb) was amplified from chromosomal DNA of B. subtilis 168 with primers BPR-EF (5'-GGAATTCAAAAAAACGAAAAACAGACTCATCAG) and BPR-ER (5'-GGAATTCCGCCCGGATCAGGGAACTCTGTATCCC). epr (1.9 kb) was amplified with primers EPR-EF (5'-AGAGAATTCAATCATGAAAAACAT) and EPR-ER (5'-GGTGAATTCTAGAAGGTTTTTGGT). The PCR products were digested with EcoRI and cloned in EcoRI-digested pUC19 to make pUC19-Epr and pUC19-Bpr, respectively. PvuII-digested pUC19-Epr and Bst1107I- and EcoRV-digested pUC19-Bpr were each ligated with XhoI linker to make pUC19-EprX and pUC19-BprX. The tetracycline resistance gene (tet; 1.7kb) excised from pUCTV2 (37) with XhoI was inserted into XhoI-digested pUC19-EprX and pUC19-BprX to make pUC19-EprTet and pUC19-BprTet, respectively. DNA fragments obtained from EcoRI-digested pUC19-EprTet and pUC19-BprTet were cloned in the EcoRI site of tet gene-deleted pUCTV2, to construct gene disruption plasmids pDBPR and pDEPR, respectively.
Inactivation of bpr and epr in B. subtilis DB104. Strain DB104 was transformed with plasmid pDBPR or pDEPR, and tetracycline-resistant clones were selected at 30°C and then grown for 36 h at 42°C (15). Five tetracycline-resistant colonies were randomly selected for each construct, and PCR was used to confirm that the strains carried the inactivated bpr or epr gene (data not shown). Primers BprP-F (5'-TAACAAACAGATAATTAGACCCATTTA) and Tet-R (5'-TAAAATTTGGTTGTGTCGTAAATTCGA) plus BprP-R (5'-CTTGACGTCTTTCAGATTGTCATCGGA) and Tet-F (5'-TGGCTGGTTACCTTGATGTATATAAA) were used to confirm the inactivation of the bpr gene. Primers BprP-F and BprP-R are located outside the cloned sequence in the pDBPR vector, and primers Tet-R and Tet-F are located in the tet gene. Inactivation of the epr gene with the tet gene was confirmed with primer pairs EprP-F (5'-ATCCGAGCTTATCGGCCCACTCGTTCC) and Tet-R and EprP-R (5'-CTGCAGGTCGACGACGGAGCATGAGAA) and Tet-F. epr- and bpr-inactivated DB104 strains were designated SB300 and PB300, respectively.
Site-directed mutagenesis. To introduce the point mutation S93E at the propeptide cleavage site in pro-Mpr, PCR mutagenesis was carried out with pMprH6 as a template and primers S93E-F (5'-CAAACCTTACAGCCTGAGAGCATTATCGGAACT) and S93E-R (5'-AGTTCCGATAATGCTCTCAGGCTGTAAGGTTTG). The resulting PCR product was digested with DpnI to remove parental pMprH6 and subsequently transformed into E. coli XL-1 Blue. The resulting plasmid was named pMprH6(S93E), and the presence of the S93E point mutation was confirmed by DNA sequencing.
SDS-PAGE and immunoblot analysis. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out by Laemmli's method (14). Western blot analysis was performed by standard protocols (25). A His probe (Santa Cruz Biotechnology) and anti-rabbit immunolgobulin G-peroxidase conjugate (Bio-Rad) were used as primary and secondary antibodies, to detect His6-tagged Mpr. The light-emitting nonradioactive ECL kit (Amersham) was used for signal detection.
Plate assay for determination of proteolytic activity. The culture supernatants from 12- to 36-h spent-culture broths of B. subtilis were placed on Luria-Bertani agar plates containing 3% (wt/vol) skim milk and Kan (25 µg/ml). Proteolytic activity was determined by observing the clear zone around colonies after 12 h of incubation at 37°C.
Determination of glutamic-acid-specific proteolytic activity. Glutamic-acid-specific protease activity was determined by a slightly modified chromogenic assay (20). Ten microliters of culture supernatant was added to 90 µl of reaction solution (50 mM Tris-Cl [pH 7.5], 2 mM CaCl2, 1 mM acetyl-Glu-p-nitroanilide [Bachem], 2% dimethylformamide). After incubation of the culture supernatant for 8 h at 37°C, the absorbance was measured at 410 nm (Bio-Rad microwell plate reader, model 550).
Protein purification. A 36-h broth culture of B. subtilis LB700 carrying either pBpr or pMpr was centrifuged (6,000 x g; 30 min), and the supernatant was obtained. Ammonium sulfate was added to 80% saturation. After 4 h of being stirred on ice, the precipitate was collected by centrifugation (8,000 x g; 30 min at 4°C), redissolved in 20 mM Tris-HCl (pH 8.0), and dialyzed overnight against the same buffer at 4°C.
For the purification of Bpr, the dialysate was concentrated with an YM-3 membrane (Amicon Corp.) and applied to a DEAE Sepharose CL-6B (Pharmacia) column equilibrated with 20 mM Tris-HCl prior to Mono-Q (Pharmacia) chromatography. Bpr was eluted from both columns by an NaCl gradient.
Purification of pro-Mpr was carried out as follows. The dialysate was applied to a DEAE Sepharose CL-6B (Pharmacia) column equilibrated with 20 mM Tris-HCl (pH 8.0). pro-Mpr was eluted from the column by an NaCl gradient. The active fractions were dialyzed against 20 mM Tris-HCl (pH 8.0), concentrated with an YM-3 membrane, loaded onto a Sephacryl S-100 (Pharmacia) column, and fractionated.
The purification of His6-tagged pro-Mpr(S93E) was performed as follows. A 36-h broth culture of B. subtilis LB700 carrying pMprH6(S93E) was centrifuged (6,000 x g; 30 min), and the supernatant was applied to a Ni-nitrilotriacetic acid superflow (QIAGEN) column. pro-Mpr(S93E) was eluted with imidazole buffer. The protein concentration was measured by Lowry's method (16).
In vitro processing of pro-Mpr by Bpr. Purified Bpr and pro-Mpr were mixed at different ratios with 20 mM Tris-Cl (pH 7.5) in a total volume of 100 µl. After incubation at 37°C for 30 min, the processing of pro-Mpr was analyzed by SDS-PAGE, and Mpr activities of mixtures were measured as above described.
In vitro processing of pro-Mpr(S93E). A mixture of purified pro-Mpr(S93E) with 20 mM Tris-Cl (pH 7.5) in a total volume of 100 µl was incubated for 4 to 12 h at 37°C. The reaction was stopped by the addition of 10 µl of trichloroacetic acid. After centrifugation, the precipitant was analyzed by immunoblotting.
Protein sequencing. The protein on a SDS gel was electroblotted onto a polyvinylidene difluoride membrane. The protein band was excised from the Coomassie brilliant blue-strained polyvinylidene difluoride membrane and subjected to N-terminal amino acid sequence analysis.
|
|
|---|
![]() View larger version (26K): [in a new window] |
FIG. 6. The deduced amino acid sequence of Mpr (A) and heteroprocessing and autoprocessing of Mpr in the extracellular milieu of B. subtilis (B). (A) Asterisks indicate the experimentally determined first amino acid residues of pro-Mpr and mature Mpr, respectively. Glutamic acid residues are underlined. (B) The initial translation product of the mpr transcript consists of a signal sequence (Pre; amino acids 1 to 34), a propeptide region (Pro; amino acids 35 to 93), and the mature enzyme (Mature; amino acids 94 to 313). Lined and dashed arrows indicate heteroprocessing by other extracellular proteases, and autoprocessing, respectively.
|
![]() View larger version (52K): [in a new window] |
FIG. 2. Characterization of processing and activation of Mpr in different B. subtilis strains. SDS-PAGE analysis (A), Western blotting (B), and artificial substrate colorimetric assay (C) of the culture supernatants of different B. subtilis strains carrying pMprH6. Lanes 1, B. subtilis 168; lanes 2, DB104; lanes 3, SB300; lanes 4, PB300; lanes 5, DB428; lanes 6, LB700. p, precursor; m, mature; Abs410nm, absorbance at 410 nm.
|
![]() View larger version (56K): [in a new window] |
FIG. 1. Plate assay of the activation of Mpr and MprH6(S93E) in different multiple extracellular protease gene-deficient B. subtilis strains. The activation of pro-Mpr was monitored by clear zones around B. subtilis colonies oversecreting Mpr for the indicated time. Lane 1, B. subtilis strain carrying pSP704 (negative control); lane 2, pMpr; lane 3, pMprH6; lane 4, pMprH6(S93E).
|
Activation of pro-Mpr by Bpr in vitro. We purified both Bpr and pro-Mpr from culture supernatants of overexpressing strains to examine pro-Mpr processing in vitro. We observed that purified Bpr activated purified pro-Mpr in vitro as detected by the production of the mature form of Mpr by SDS-PAGE analysis (Fig. 3A) and by the activation of Mpr in the colorimetric assay for glutamic-acid-specific proteolytic activity (Fig. 3B). From these results, we conclude that Bpr specifically converts inactive pro-Mpr to active Mpr through proteolytic processing of the Mpr propeptide.
![]() View larger version (42K): [in a new window] |
FIG. 3. In vitro processing of pro-Mpr by Bpr. SDS-PAGE analysis (A) and artificial substrate colorimetric assay (B) of purified pro-Mpr processed by purified Bpr in vitro. Purified pro-Mpr (3.3 µg) was added to each mixture (100 µl) in the results shown in lanes 2 to 5. Lane 1, 4.5 µg of purified Bpr; lane 2, 4.5 µg of Bpr; lane 3, 1.5 µg of Bpr; lane 4, 0.75 µg of Bpr; lane 5, pro-Mpr. b, Bpr; p, pro-Mpr; m, mature Mpr; Abs410nm, absorbance at 410 nm..
|
![]() View larger version (56K): [in a new window] |
FIG. 4. Characterization of processing and activation of Mpr(S93E) in different B. subtilis strains. SDS-PAGE analysis (A), Western blotting (B), and artificial substrate colorimetric assay (C) of the culture supernatants of different B. subtilis strains carrying pMprH6(S93E). Lane 1, B. subtilis 168; lane 2, DB104; lane 3, SB300; lane 4, PB300; lane 5, DB428; lane 6, LB700. p, precursor; m, mature.
|
![]() View larger version (37K): [in a new window] |
FIG. 5. In vitro autoprocessing of Mpr(S93E). Time course processing of purified pro-Mpr(S93E) was analyzed by immunoblotting. The numbers (0, 4, 8, and 12) indicate the incubation time in hours. p, precursor; m, mature.
|
|
|
|---|
Proteolytic activity was observed on skim milk-agar plates in an aprE nprE mutant carrying pMpr but not in an aprE nprE epr bpr mutant carrying pMpr, suggesting that Mpr might require Epr or Bpr for activation rather than being autoprocessed. To identify which was required for Mpr activation, we investigated pro-Mpr processing in bpr-deficient and epr-deficient derivatives of DB104 (PB300 and SB300, respectively) (Table 1). The skim milk plate assay indicated that bpr, but not epr, was required for Mpr processing (Fig. 1).
This finding was confirmed by SDS-PAGE analysis with Coomassie blue staining, demonstrating that pro-Mpr (33 kDa) was accumulated and not converted into the mature form (28 kDa) in culture supernatants of bpr-deficient strains carrying pMprH6 (Fig. 2A). However, a 28-kDa form could be detected in bpr-deficient strains PB300 and DB428 by immunoblotting (Fig. 2B). To determine whether pro-Mpr was properly processed in the bpr-deficient strains or nonspecifically processed by other proteolytic activities to an apparently mature size, we examined the glutamic-acid-specific protease activity in various B. subtilis strains carrying pMprH6. As shown in Fig. 2C, no glutamyl proteolytic activity was observed in the culture supernatants of bpr-deficient strains carrying pMprH6. This suggests that the 28-kDa protein detected by Western blotting in the bpr-deficient strains is an inactive form of MprH6, although it is processed at the N terminus because the C-terminal His6 tag is being detected.
These in vivo findings are supported by in vitro studies demonstrating that purified Bpr processes purified pro-Mpr to a proteolytically active form of the expected size in vitro (Fig. 3). We conclude from these in vivo and in vitro results that Bpr specifically processes pro-Mpr to mature Mpr in vivo. This heteroprocessing activity represents a novel function of bacillopeptidase F in B. subtilis.
We cannot exclude the possibility that subtilisin (AprE) and neutral protease (NprE) also play roles in Mpr processing. We could not determine whether Mpr was activated by AprE and NprE by the skim milk plate assay, because strains that are aprE+ nprE+ (strains 168 and PB100) form clear zones regardless of whether they are overexpressing Mpr. However, we found significant glutamyl proteolytic activities and fully processed (28-kDa) Mpr bands in the culture supernatants of wild-type strain 168 and also in bpr-deficient PB100, suggesting that Apr and/or Npr could be involved in Mpr processing (data not shown). Multiple proteases may allow pro-Mpr to be more rapidly and fully converted into an active form in the extracellular milieu. Epr had little effect on Mpr processing (Fig. 2A and B). However, we observed that Mpr had slightly lower levels of glutamyl proteolytic activity in the absence of Epr than in the presence of Epr (Fig. 2C). This result implies that Epr contributes to Mpr processing.
In pathogenic bacteria, extracellular proteases can enhance bacterial virulence through degradation of critical host proteins and by mimicking the activity of host regulatory proteases that control important zymogen systems (6). In the staphylococcal extracellular proteolytic system, zymogen activation by other extracellular proteases was recently reported (26). In nonpathogenic bacteria such as B. subtilis, extracellular proteases may have other functions. As mentioned, all extracellular proteases of B. subtilis are known to have no effect on either exponential growth in complex medium or sporulation (29). However, production and secretion of extracellular proteases increase during postexponential growth (7). During that period, protein degradation by extracellular proteases supplies nutrients for the cells. Moreover, the extracellular proteases play a role in the activation of other proteins. For example, WprA, Apr, and Vpr are reported to activate an antimicrobial subtilin (3). The present study shows a novel function of extracellular proteases, which is to activate other extracellular proteases in B. subtilis.
Because Mpr is a glutamic-acid-specific endopeptidase that specifically forms a peptide bond after the P1 glutamic acid site (20) but does not have a P1 glutamic acid at its own processing site, we constructed the His6-tagged Mpr(S93E) mutant to determine its effect on processing. Interestingly, the S93E mutant was fully processed into an active form in all the B. subtilis strains tested, regardless of protease deficiencies (Fig. 4), indicating that pro-Mpr(S93E) was activated by autoprocessing. The in vitro studies demonstrated that purified pro-Mpr(S93E) was processed to a proteolytically active form of the expected size in vitro by the time course (Fig. 5). From these in vivo and in vitro results, we conclude that the S93E mutant allows autoprocessing. Moreover, we confirmed that processing of Mpr(S93E) occurs at the proper site between amino acids 93 and 94 (Fig. 6) by N-terminal sequence analysis of the mature form from LB700. As in the results shown in Fig. 4C, there was an appoximately twofold decrease in activity in the LB700 strain that lacks seven exopeptidases. The decrease in Mpr activity in LB700 carrying pMpr(S93E) may be due to the absence of the wprA gene product (LB700 is the only strain examined here which lacks wprA) which is associated with the protein secretion apparatus in B. subtilis (1). Absence of WprA might influence the secretion of Mpr and so affect Mpr processing. Alternatively, the decrease might be due to effects of the multiple mutations on growth rate or other factors that affect the colorimetric assay. Regardless, the processing of pro-Mpr(S93E) in the absence of Bpr and other exoproteases suggests strongly that S93E allows autoprocessing.
With regards to the autoprocessing mechanism, the alteration of serine into glutamic acid residue in pro-Mpr might help its propeptide fit properly into the P1 pocket for processing by self cleavage. This indicates that the propeptide sequence determines whether Mpr undergoes heteroprocessing or autoprocessing. This alteration of the processing mechanism could be explained in the viewpoint of the molecular evolution of proteases. It could be deduced that Mpr was originally activated by autoprocessing like other extracellular proteases and might have evolved to the present form so that it could be activated by other proteases for posttranslocational regulation. Moreover, the role of Mpr propeptide remains to be resolved in future work, since propeptides are known to be involved in guiding the correct folding or inhibition of protease activity (11).
In summary, we report that glutamic-acid-specific Mpr could be specifically activated by a heteroprocessing mechanism in B. subtilis by Bpr protease and also that only a single amino acid exchange at the Mpr processing site switches heteroprocessing to autoprocessing.
We are grateful to S. L. Wong for providing B. subtilis DB428. We thank F. Meinhardt for supplying plasmid pUCTV2.
Present address: Metabolic Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea. ![]()
|
|
|---|
-amylase by Bacillus subtilis. Appl. Environ. Microbiol. 64:2875-2881.
37 promoter in vivo. Proc. Natl. Acad. Sci. USA 81:1184-1188.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»